DOCSLIB.ORG

Osilodrostat (LCI699) a Phase II, Open-Label, Dose Titration, Multi-Center

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Osilodrostat (LCI699) a Phase II, Open-Label, Dose Titration, Multi-Center Clinical Development Osilodrostat (LCI699) Oncology Clinical Trial Protocol CLCI699C1201 / NCT02468193 A Phase II, open-label, dose titration, multi-center study to assess the safety/tolerability and efficacy of osilodrostat in patients with all types of endogenous Cushing’s syndrome except Cushing’s disease Document type Amended protocol version EUDRACT number Not applicable Version number 04 (Clean) Development phase II Document status Final Release date 31-Jul-2018 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Template version 6-Apr-2017 Novartis Confidential Page 2 Amended Protocol Version 04 (Clean) Protocol No. CLCI699C1201 Table of contents Table of contents .................................................................................................................2 List of tables ........................................................................................................................5 List of figures ......................................................................................................................6 List of abbreviations ............................................................................................................7 Amendment 4 (31-Jul-2018) ...............................................................................................9 Summary of previous amendments ...................................................................................10 Amendment 3 (07-Aug-2017) ...........................................................................................10 Amendment 2 (11-Nov-2016) ...........................................................................................11 Amendment 1 (29-Feb-2016)............................................................................................14 Protocol summary:.............................................................................................................16 1 Background........................................................................................................................18 1.1 Overview of disease pathogenesis, epidemiology and current treatment..............18 1.1.1 Epidemiology and pathogenesis of Cushing’s syndrome (CS).............18 1.1.2 Current treatment modalities.................................................................18 1.2 Introduction to investigational treatment(s) and other study treatment(s).............19 1.2.1 Overview of osilodrostat (LCI699).......................................................19 2 Rationale............................................................................................................................25 2.1 Study rationale and purpose...................................................................................25 2.2 Rationale for the study design ...............................................................................25 2.3 Rationale for dose and regimen selection..............................................................26 2.4 Rationale for choice of combination drugs............................................................27 2.5 Rationale for choice of comparators drugs............................................................27 2.6 Benefit-Risk Assessment of osilodrostat in study population ...............................27 28 3 Objectives and endpoints...................................................................................................29 4 Study design ......................................................................................................................32 4.1 Description of study design ...................................................................................32 4.2 Timing of interim analyses and design adaptations...............................................33 4.3 Definition of end of the study................................................................................33 4.4 Early study termination..........................................................................................33 5 Population..........................................................................................................................34 5.1 Patient population ..................................................................................................34 5.2 Inclusion criteria ....................................................................................................34 5.3 Exclusion criteria...................................................................................................36 6 Treatment...........................................................................................................................38 6.1 Study treatment......................................................................................................38 Novartis Confidential Page 3 Amended Protocol Version 04 (Clean) Protocol No. CLCI699C1201 6.1.1 Dosing regimen .....................................................................................38 6.1.2 Ancillary treatments..............................................................................39 6.1.3 Rescue medication ................................................................................39 6.1.4 Guidelines for continuation of treatment ..............................................39 6.1.5 Treatment duration................................................................................39 6.2 Dose escalation guidelines.....................................................................................40 6.3 Dose modifications ................................................................................................40 6.3.1 Dose modification and dose delay ........................................................40 6.3.2 Follow-up for toxicities.........................................................................44 6.3.3 Anticipated risks and safety concerns of the study drug.......................45 6.4 Concomitant medications ......................................................................................45 6.4.1 Permitted concomitant therapy .............................................................45 6.4.2 Prohibited concomitant therapy ............................................................46 6.5 Patient numbering..................................................................................................47 6.6 Study drug preparation and dispensation...............................................................47 6.6.1 Study drug packaging and labeling.......................................................48 6.6.2 Drug supply and storage........................................................................48 6.6.3 Study drug compliance and accountability ...........................................48 6.6.4 Disposal and destruction .......................................................................49 7 Visit schedule and assessments .........................................................................................49 7.1 Study flow and visit schedule................................................................................49 7.1.1 Screening...............................................................................................58 7.1.2 Run-in period ........................................................................................59 7.1.3 Treatment period ...................................................................................59 7.1.4 Discontinuation of study treatment .......................................................59 7.1.5 Follow up for safety evaluations...........................................................61 7.1.6 Lost to follow-up...................................................................................61 7.2 Assessment types ...................................................................................................61 7.2.1 Efficacy assessments.............................................................................61 7.2.2 Safety and tolerability assessments.......................................................62 7.2.3 Pharmacokinetics ..................................................................................70 71 7.2.5 Resource utilization...............................................................................72 7.2.6 Patient reported outcomes.....................................................................72 8 Safety monitoring and reporting........................................................................................73 8.1 Adverse events.......................................................................................................73 8.1.1 Definitions and reporting ......................................................................73 Novartis Confidential Page 4 Amended Protocol Version 04 (Clean) Protocol No. CLCI699C1201 8.1.2 Laboratory test abnormalities................................................................74 8.1.3 Adverse events of special interest.........................................................75 8.2 Serious adverse events...........................................................................................76 8.2.1 Definitions.............................................................................................76 8.2.2 Reporting...............................................................................................76 8.3 Pregnancies ............................................................................................................77
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al
    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
    [Show full text]
  • Systemic Effect of Inhaled Corticosteroids on Adrenal
    Issa-El-Khoury et al. Allergy, Asthma & Clinical Immunology (2015) 11:9 DOI 10.1186/s13223-015-0075-z ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY POSITION ARTICLE AND GUIDELINES Open Access CSACI position statement: systemic effect of inhaled corticosteroids on adrenal suppression in the management of pediatric asthma Karine Issa-El-Khoury1, Harold Kim2,3, Edmond S Chan4, Tim Vander Leek5 and Francisco Noya1* Abstract Asthma is a chronic inflammatory disease of the airways that affects a growing number of children and adolescents. Inhaled corticosteroids (ICS) are the mainstay of treatment in persistent asthma, with a stepwise approach to increasing doses of ICS depending on asthma severity and control. ICS have known local and systemic side effects, of which adrenal suppression is still under-recognized. The latter is associated with chronic exposure and higher doses, although it has rarely been reported in children receiving low doses for a short period of time. The Canadian Society of Allergy and Clinical Immunology (CSACI) therefore recommends that physicians screen for adrenal suppression in children receiving high doses for more than 6 months and to consider screening those on medium dose if the risk is deemed higher by factors that increase an individual’s systemic corticosteroid exposure. Morning serum cortisol level can be used as a screening tool and abnormal results or normal results with a high index of suspicion should be confirmed with low-dose ACTH stimulation tests. Keywords: Asthma, Inhaled corticosteroids, Fluticasone, Adrenal suppression Background reducing asthma mortality. Most patients can achieve Asthma affects about 10% of the Canadian population, and asthma control using relatively low doses of ICS, which 50-80% of children affected develop it before the age of 5 will produce maximum or near-maximum clinical benefit, years [1].
    [Show full text]
  • 5-HT Receptor Agonist Befiradol Reduces Fentanyl-Induced
    5-HT1A Receptor Agonist Befiradol Reduces Fentanyl-induced Respiratory Depression, Analgesia, and Sedation in Rats Jun Ren, Ph.D., Xiuqing Ding, B.Sc., John J. Greer, Ph.D. ABSTRACT Background: There is an unmet clinical need to develop a pharmacological therapy to counter opioid-induced respiratory depression without interfering with analgesia or behavior. Several studies have demonstrated that 5-HT1A receptor agonists alleviate opioid-induced respiratory depression in rodent models. However, there are conflicting reports regarding their effects on analgesia due in part to varied agonist receptor selectivity and presence of anesthesia. Therefore the authors performed a Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/122/2/424/267207/20150200_0-00031.pdf by guest on 27 September 2021 study in rats with befiradol (F13640 and NLX-112), a highly selective 5-HT1A receptor agonist without anesthesia. Methods: Respiratory neural discharge was measured using in vitro preparations. Plethysmographic recording, nociception testing, and righting reflex were used to examine respiratory ventilation, analgesia, and sedation, respectively. Results: Befiradol (0.2 mg/kg, n = 6) reduced fentanyl-induced respiratory depression (53.7 ± 5.7% of control minute ven- tilation 4 min after befiradol vs. saline 18.7 ± 2.2% of control, n = 9; P < 0.001), duration of analgesia (90.4 ± 11.6 min vs. saline 130.5 ± 7.8 min; P = 0.011), duration of sedation (39.8 ± 4 min vs. saline 58 ± 4.4 min; P = 0.013); and induced baseline hyperventilation, hyperalgesia, and “behavioral syndrome” in nonsedated rats. Further, the befiradol-induced alleviation of opioid-induced respiratory depression involves sites or mechanisms not functioning in vitro brainstem–spinal cord and medul- lary slice preparations.
    [Show full text]
  • Prior Authorization Cushing’S – Isturisa® (Osilodrostat Tablets)
    Cigna National Formulary Coverage Policy Prior Authorization Cushing’s – Isturisa® (osilodrostat tablets) Table of Contents Product Identifier(s) National Formulary Medical Necessity ................ 1 64705 Conditions Not Covered....................................... 2 Background .......................................................... 2 References .......................................................... 3 Revision History ................................................... 3 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Yasakli Maddeler
    YASAKLI MADDELER Ülkemizde yarış atlarında kullanılan/kullanılma ihtimali olan ilaçların/maddelerin belirlenmesinde; ilacın farmakolojisi (öncelikle etkisi, etki grubu), farmasötik şekli, kullanılma yolu, kullanılma alanı, yarış sonucunu etkileme durumu, ulusal mevzuata göre veteriner hekimlikte ve/veya yarış atlarında kullanmak için ruhsatlı/izinli olup-olmama durumu, etiket-dışı kullanılma gibi hususlar dikkate alınmıştır. Eşik değeri (Threshold level) olan maddelerin (vücutta şekillenirler, çevre ve yem kaynaklı olabilirler) miktarı, belirlenen miktarı aştığında yasaklı-madde kullanılması/doping ihlali olarak değerlendirilir. Tedavide kullanılan/tarama limiti (Screening level) olan maddelerle ilgili değerlendirmede; bu maddelerle ilgili olarak yapılan doping analizlerinde ölçülen miktar, idrarda/plazmada belirlenen tarama değerini aştığında yasaklı madde kullanılması/doping-ihlali olarakdeğerlendirilir. Ana madde yanında, izomeri, metaboliti, metabolit izomeri, tuzları, esterleri, eterleri, diğer türevleri, ön-ilaç da yasaklı-madde listesinde yer alır; doping analizinde ortaya konulmaları doping ihlali olarak değerlendirilir. Maddeler ve yasaklı uygulamalar 6 başlık altında toplanmıştır. Bu liste ilgili uluslararası kuruluşların mevzuat ve düzenlemeleri ile ilgili maddelerin Farmakolojik özellikleri ve etkileri dikkate alınarak hazırlanmıştır. 1. YasaklıMaddeler Yasaklı maddeler; yarış atlarında tıbbi olarak kullanım yeri olmayan, atın yarış performansını açık şekilde etkileyen maddelerdir. İllegal kullanılan maddeler (Türkiye’de veteriner
    [Show full text]
  • Update on Medical Treatment for Cushing's Disease
    Cuevas-Ramos et al. Clinical Diabetes and Endocrinology (2016) 2:16 DOI 10.1186/s40842-016-0033-9 REVIEWARTICLE Open Access Update on medical treatment for Cushing’s disease Daniel Cuevas-Ramos1, Dawn Shao Ting Lim2 and Maria Fleseriu2* Abstract Cushing’s disease (CD) is the most common cause of endogenous Cushing’s syndrome (CS). The goal of treatment is to rapidly control cortisol excess and achieve long-term remission, to reverse the clinical features and reduce long-term complications associated with increased mortality. While pituitary surgery remains first line therapy, pituitary radiotherapy and bilateral adrenalectomy have traditionally been seen as second-line therapies for persistent hypercortisolism. Medical therapy is now recognized to play a key role in the control of cortisol excess. In this review, all currently available medical therapies are summarized, and novel medical therapies in phase 3 clinical trials, such as osilodrostat and levoketoconazole are discussed, with an emphasis on indications, efficacy and safety. Emerging data suggests increased efficacy and better tolerability with these novel therapies and combination treatment strategies, and potentially increases the therapeutic options for treatment of CD. New insights into the pathophysiology of CD are highlighted, along with potential therapeutic applications. Future treatments on the horizon such as R-roscovitine, retinoic acid, epidermal growth factor receptor inhibitors and somatostatin-dopamine chimeric compounds are also described, with a focus on potential
    [Show full text]
  • Auspar Attachment 1: Product Information for Progesterone
    Attachment 1: Product information for AusPAR - ORIPRO - Progesterone - Orion Laboratories Ltd (T/A Perrigo Australia) - PM-2018-04477-1-5 FINAL 7 February 2020. This is the Product Information that was approved with the submission described in this AusPAR. It may have been superseded. For the most recent PI, please refer to the TGA website at <https://www.tga.gov.au/product-information-pi> AUSTRALIAN PRODUCT INFORMATION – ORIPRO® (PROGESTERONE) PESSARIES 1 NAME OF THE MEDICINE Progesterone 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Oripro Pessaries contain as active substance 100mg or 200mg of progesterone (micronized) in hard fat. 3 PHARMACEUTICAL FORM Vaginal Pessaries - Opaque, bullet-shaped waxy, solid masses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oripro Pessaries are indicated for: 1. Assisted reproductive technology (ART) treatment of infertile women with progesterone deficiency, requiring progesterone supplementation or replacement to support embryo implantation and maintain initial pregnancy. 2. Prevention of preterm birth in singleton pregnancies at risk due to; · Shortened cervix 1 Attachment 1: Product information for AusPAR - ORIPRO - Progesterone - Orion Laboratories Ltd (T/A Perrigo Australia) - PM-2018-04477-1-5 FINAL 7 February 2020. This is the Product Information that was approved with the submission described in this AusPAR. It may have been superseded. For the most recent PI, please refer to the TGA website at <https://www.tga.gov.au/product-information-pi> The dosage of progesterone for prevention of preterm birth is 200 mg daily (at night). Treatment can be initiated during the second trimester (16-24 weeks gestation) and is to be continued to the end of the 36th week of gestation or until delivery.
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates Et Al
    US 20150.072964A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates et al. (43) Pub. Date: Mar. 12, 2015 (54) NOVELMETHODS filed on Apr. 14, 2012, provisional application No. 61/624.293, filed on Apr. 14, 2012, provisional appli (71) Applicant: INTRA-CELLULAR THERAPIES, cation No. 61/671,713, filed on Jul. 14, 2012, provi INC., New York, NY (US) sional application No. 61/671,723, filed on Jul. 14, 2012. (72) Inventors: Sharon Mates, New York, NY (US); Robert Davis, New York, NY (US); Publication Classification Kimberly Vanover, New York, NY (US); Lawrence Wennogle, New York, (51) Int. Cl. NY (US) C07D 47L/6 (2006.01) A613 L/4985 (2006.01) (21) Appl. No.: 14/394,469 A6II 45/06 (2006.01) (52) U.S. Cl. (22) PCT Fled: Apr. 14, 2013 CPC .............. C07D 471/16 (2013.01); A61K 45/06 (2013.01); A61 K3I/4985 (2013.01) (86) PCT NO.: PCT/US13A36512 USPC ...... 514/171; 514/250; 514/211.13: 514/217; S371 (c)(1), 514/214.02: 514/220 (2) Date: Oct. 14, 2014 (57) ABSTRACT Use of particular substituted heterocycle fused gamma-car Related U.S. Application Data boline compounds as pharmaceuticals for the treatment of (60) Provisional application No. 61/624.291, filed on Apr. agitation, aggressive behaviors, posttraumatic stress disorder 14, 2012, provisional application No. 61/624,292, or impulse control disorders. US 2015/0072964 A1 Mar. 12, 2015 NOVEL METHODS One type of ICD is Intermittent Explosive Disorder (IED) which involves violence or rage. There is a loss of control CROSS REFERENCE TO RELATED grossly out of proportion to any precipitating psychosocial APPLICATIONS stresses.
    [Show full text]
  • Isturisa : EPAR
    14 November 2019 EMA/653461/2019 Corr.2 Committee for Medicinal Products for Human Use (CHMP) Assessment report Isturisa International non-proprietary name: osilodrostat Procedure No. EMEA/H/C/004821/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ..................................................................................... 6 1.2. Steps taken for the assessment of the product ........................................................ 7 2. Scientific discussion ................................................................................ 9 2.1. Problem statement ............................................................................................... 9 2.1.1. Disease or condition .......................................................................................... 9 2.1.2. Epidemiology .................................................................................................... 9 2.1.3. Aetiology and pathogenesis ...............................................................................
    [Show full text]